Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
Key Highlights
- ➤Inhibikase management scheduled investor meetings at Jefferies and Evercore healthcare conferences
- ➤IKT-001 Phase 3 IMPROVE-PAH study actively enrolling patients globally
- ➤IMPROVE-PAH spans approximately 180 clinical sites worldwide
- ➤IKT-001 is a once-daily oral anti-proliferative candidate for Pulmonary Arterial Hypertension
WILMINGTON, Del., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today announced that the Company’s management will be participating in the following investor conferences during the month of November and December 2026.
Jefferies Global Healthcare Conference November 16–19, 2026 London, United Kingdom Presentation Details: Fireside Chat with Mark Iwicki, CEO of Inhibikase and Dennis Ding, Jefferies Research on Monday, November 16 at 3:00pm (GMT) Meeting Details: one-on-one meetings on Monday, November 16 and Tuesday, November 17 Webcast: Click here
Get started
Create a free account to read the full story.